小儿咳喘灵颗粒联合丙酸氟替卡松治疗小儿咳嗽变异型哮喘的临床疗效观察

CLINICAL OBSERVATION ON TREATMENT OF COUGH VARIANT ASTHMA IN CHILDREN WITH CHILDREN′S COUGH VARIANT ASTHMA TREATED BY XIAOER KECHUANLING GRANULE GRANULE AND FLUTICASONE PROPIONATE

目的探讨小儿咳喘灵颗粒联合丙酸氟替卡松治疗小儿咳嗽变异型哮喘的临床疗效。方法选取2017年3月—2018年3月我院收治的84例咳嗽变异型哮喘患儿为研究对象,随机分为观察组与对照组,各42例。对照组患儿给予西医常规治疗联合丙酸氟替卡松治疗,观察组患儿在对照组的基础上给予小儿咳喘灵颗粒治疗,治疗结束后评价二组患儿临床疗效,对比治疗前后二组患儿嗜酸细胞阳离子蛋白(ECP)、嗜酸粒细胞(EOS)、白细胞介素-5(IL-5)水平及肺功能指标变化情况,并观察二组患儿不良反应发生情况。结果观察组患儿的临床疗效显著高于对照组(P<0.05);治疗前,二组患儿ECP、EOS、IL-5水平及肺功能指标比较差异无统计学意义(P>0.05),治疗后,二组患儿的ECP、EOS、IL-5水平均较治疗前降低(P<0.05),且观察组患儿ECP、EOS、IL-5水平低于对照组(P<0.05);治疗后二组患儿FEV1、FVC及FEV1/FVC值均较治疗前明显升高,且观察组患儿的FEV1、FVC及FEV1/FVC值显著高于对照组(P<0.05)。结论小儿咳喘灵颗粒联合丙酸氟替卡松治疗小儿咳嗽变异型哮喘临床疗效显著,可有效改善患儿炎性因子水平、肺功能,安全性高,值得临床推广。

Objective To explore the clinical efficacy of Xiaoer Kechuanling Granule combined with fluticasone propionate in the treatment of children with cough variant asthma.Methods Eighty-four children with cough variant asthma admitted to Panzhihua Second People′s Hospital from March 2017 to March 2018 were selected and were randomly divided into study group and control group,42 cases in each group.The control group was treated with routine western medicine combined with fluticasone propionate,while the study group was treated with Xiaoer Kechuanling Granule on the basis of the control group.The clinical efficacy of the twogroups was evaluated after the treatment.Eosinophilic cationic protein(ECP),eosinophil(EOS)and leukocyte mediator were compared before and after the treatment.The levels of IL-5 and the changes of pulmonary function were observed,and the occurrence of adverse reactions in the two groups was also observed.Results The clinical effect of the study group was significantly higher than that of the control group(P<0.05).Before treatment,there was no statistically significant difference in ECP,EOS,IL-5 levels and pulmonary function index between the two groups(P>0.05).After treatment,the ECP,EOS,IL-5 levels of the two groups were lower than those before treatment(P<0.05),and the ECP,EOS levels of the study group were lower than those of the control group(P<0.05).The level of IL-5 was lower than that of control group(P<0.05).The values of FEV1,FVC and FEV1/FVC in the two groups were significantly higher than those before treatment,and the FEV1,FVC and FEV1/FVC in the study group were significantly higher than those of control group.Conclusion Xiaoer Kechuanling Granule combined with fluticasone propionate has significant clinical effect on treating children with cough variant asthma.It can effectively improve the level of inflammatory factors and pulmonary function of children with high safety,and is worthy of clinical promotion.